Skip to main content

Table 4 The results of analysis of selected proteins concentrations

From: Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study

Table 4

Control group

Stage I/II

Stage III

Stage IV

Stage V

p

N=24

N=20

N=20

N=20

N=20

Fetuin A [ng/ml]

102,9±61,1

110,6±74,7

120,1±82,2

102,1±77,4

125,2±63,3

NS

MMP-2 [ng/ml]

103,0±55,7

161,6±105,7

213,0±187,8

270,9±144,5**

228,5±117,6*

P=0,002

MMP-9 [ng/ml]

18,4±5,6

16,9±6,5

17,4±5,9

18,0±6,5

18,0±7,6

NS

TIMP-1 [ng/ml]

23,6±2,9

19,9±2,5**

22,1±2,7

21,4±2,5

21,1±1,9*

P=0,002

TIMP-2 [ng/ml]

21,0±2,8

21,8±2,2

22,9±1,4*

21,5±2,0

22,0±1,7

NS

MMP-2/TIMP-2

4,7±2,9

7,4±4,6

9,2±7,9

11,9±6,9**

10,5±5,8*

P=0,002

MMP-9/TIMP-1

0,93±0,43

0,80±36

0,77±0,26

0,81±0,39

0,83±0,39

NS

Osteocalcin [ng/ml]

6,2±4,0

7,8±4,5

7,0±3,8

5,0±4,4

3,9±4,1

NS

Osteopontin [ng/ml]

38,0±22,5

11,3±5,1

29,7±33,6

29,8±29,9

28,7±19,7

NS

Osteoprotegerin

[pmol/l]

6,0±5,3

4,5±5,6

6,3±5,4

6,4±5,1

8,7±6,1

NS

MGP [ng/ml]

103,7±30,4

105,8±44,4

103,5±29,5

100,7±41,9

88,7±55,0

NS

  1. *p<0.05; **p<0.01 vs control